Argomenti trattati
The Advanced Research Projects Agency for Health (ARPA-H) has appointed Alicia Jackson, Ph.D. as its new leader. Jackson’s vision aims to transform health innovation as the agency grapples with ongoing controversies surrounding vaccines, exploring alternatives that may one day eliminate their necessity. Her appointment comes during the Biden administration amid a critical period for public health.
In a recent interview, Jackson discussed the limitations of traditional vaccination methods. She indicated that reliance on vaccines may soon become outdated. Jackson highlighted the existence of various technologies that could enhance our defense against infectious diseases, potentially rendering the debate over vaccine efficacy obsolete.
The facts
Jackson’s strategy focuses on advancing innovative methods to combat infectious diseases, including monoclonal antibodies. ARPA-H has allocated up to $30 million to Vanderbilt University Medical Center to develop a cutting-edge artificial intelligence algorithm for generating effective antibodies against various illnesses. This initiative is part of a broader investment totaling $204 million aimed at discovering new viral antigens.
Jackson cited the success of Beyfortus, an antibody developed by AstraZeneca and Sanofi that protects infants from respiratory syncytial virus (RSV). She noted, “This antibody provides passive immunity for about five months,” raising questions about the potential for enhancing these antibodies for longer-lasting protection.
Challenges and limitations of monoclonal antibodies
Experts caution that monoclonal antibodies, while promising, have significant drawbacks. Dr. Anna Durbin from Johns Hopkins University noted that these therapies do not create immunological memory, necessitating repeated doses for continued protection. She stated, “For certain diseases, such as the flu, annual monoclonal antibody treatments may suffice. However, for more persistent diseases like measles or polio, the long-term immunity provided by vaccines remains irreplaceable.”
Moreover, administering monoclonal antibodies typically involves IV infusion, which can be costly and logistically challenging. Durbin added, “Many nations cannot afford such treatments,” highlighting a significant barrier to widespread use.
ARPA-H’s broader initiatives
Before Jackson’s leadership, ARPA-H faced internal challenges, including the resignation of its chief data officer amid funding disputes over mRNA vaccine research. Nonetheless, Jackson views mRNA technology as valuable for addressing other health issues, such as cancer treatments. “The technology is evolving, but its deployment depends on decisions made by Congress and regulatory authorities,” she remarked.
ARPA-H is also diversifying its focus beyond vaccines and therapeutics. Recently, the agency announced a funding initiative of up to $156 million to improve indoor air quality and mitigate the spread of pathogens and allergens. Jason Roos, acting director of ARPA-H, noted that this initiative would significantly enhance public health through advanced detection and management of indoor air threats.
Jackson’s leadership journey
Jackson describes her return to government as a dream realized after previously working at the Defense Advanced Research Projects Agency (DARPA). She believes her experience as a CEO of health startups has shaped her approach to ARPA-H. “Building an organization from the ground up has given me unique insights into fostering a culture of innovation and efficiency,” she explained.
Currently leading a team of about 30 program managers, Jackson envisions expanding her workforce by hiring an additional 20. These managers, often from diverse backgrounds in academia and industry, are critical to ARPA-H’s mission. They are empowered to pitch innovative ideas and act like mini-CEOs. Recent projects funded by ARPA-H include advancements in gene editing therapies and novel treatments for pediatric cancers.
Competing in the global biotech landscape
In a recent interview, Jackson discussed the limitations of traditional vaccination methods. She indicated that reliance on vaccines may soon become outdated. Jackson highlighted the existence of various technologies that could enhance our defense against infectious diseases, potentially rendering the debate over vaccine efficacy obsolete.0
In a recent interview, Jackson discussed the limitations of traditional vaccination methods. She indicated that reliance on vaccines may soon become outdated. Jackson highlighted the existence of various technologies that could enhance our defense against infectious diseases, potentially rendering the debate over vaccine efficacy obsolete.1